Abstract
AbstractBackgroundUsing a variety of cell and animal model systems we demonstrate that the cytosolic antibody receptor and E3 ligase TRIM21 plays a critical role in antibody‐mediated protection against tau pathologyMethodExperiments with organotypic hippocampal slice cultures and in vivo studies in mouse models were conducted to study the role of TRIM21 in tau immunotherapy.ResultWe demonstrate that tau:antibody complexes were internalised to the cytosol of neurons, enabling TRIM21 engagement and thereby protecting against seeded aggregation. Crucially, antibody‐mediated protection against tau pathology was lost in mice lacking TRIM21ConclusionThe cytosolic compartment provides a site of immunotherapeutic protection, which can help in the design of antibody‐based therapies in neurodegenerative disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
